生物制剂治疗系统性红斑狼疮新进展

Update of biological agents in the treatment of systemic lupus erythematosus

系统性红斑狼疮是一种表现多样的慢性自身免疫病,可累及全身。糖皮质激素及免疫抑制剂为主的传统药物对部分SLE患者的疗效欠佳,且长期应用毒副作用大。生物制剂的出现为SLE治疗带来新的选择,临床应用中也取得了一定成效。本文就生物制剂在红斑狼疮临床治疗中的新进展作一综述。

Systemic lupus erythematosus is a chronic autoimmune disease characterized by variable clinical manifestations that can affect many organs and can cause organs damage. Some patients with SLE do not respond well to conventional drugs, including corticosteroids and immunosuppressive agents, and the adverse reaction is obvious after long-term treatment. The emergence of biological agents has brought some new choices for the therapy of SLE. Those agents has achieved remarkable effect in clinical practice. The recent advances on the biological agents for SLE were reviewed in this paper.